| Human Molecular Genetics | Pages |
Huntingtin interacts with a family of WW domain proteins
Introduction
Results
Isolation of huntingtin yeast partners (HYPs)
Description of huntingtin N-terminal interactors
HYPA, HYPB and HYPC are members of a WW domain family
Expression of HYPA, HYPB and HYPC
Interaction of HYPA and HYPB with huntingtin in the yeast two-hybrid system
WW domain HYPs interact via huntingtin's N-terminal proline-rich segment
WW domain partners bind to huntingtin in HD lymphoblastoid cells
Discussion
Materials And Methods
HD expression constructs
HYP expression clones
Control plasmids
Yeast two-hybrid screens
Protein extracts, invitro binding, immunoprecipitation and immunoblot analyses
Northern analysis
Accession numbers
Acknowledgements
References
Huntingtin interacts with a family of WW domain proteins
INTRODUCTION
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder featuring progressively worsening chorea, psychiatric disturbances and cognitive impairment due to neuronal cell loss in the basal ganglia and the cerebral cortex (1,2). It is caused by expansion of a polymorphic CAG trinucleotide repeat (6-34 units) (3) that encodes a glutamine tract in huntingtin, a ~350 kDa protein of unknown function that is essential for normal embryonic development (4-6) and neurogenesis (7). The length of the CAG repeat on disease chromosomes (35 to >100 units) is correlated with age at neurologic onset, such that the majority of cases show adult onset due to ~42-48 CAGs, while the longest arrays (>60 units) cause juvenile onset HD (3,8).
The HD mutation confers a new property on huntingtin that is specifically deleterious to target neurons and is likely to be subtle, given the late age of onset and long time course of the disorder (9-11). The glutamine tract extended by the HD defect is adjacent to a mildly polymorphic proline-rich segment (12) in huntingtin's N-terminus and alters the physical properties of the mutant protein as evidenced by decreased mobility on SDS-PAGE (13-17) and increased reactivity with specific monoclonal antibody reagents (7,18). Aberrant behavior of mutant huntingtin is also reflected by the formation of cytoplasmic and nuclear inclusions in HD brain (19), although it is not yet clear whether these are a cause or a consequence of the pathogenic process (20). The distinct physical properties of mutant huntingtin suggest that HD pathology may be triggered by an altered interaction with another protein, either a change in the association with a normal binding partner or an abnormal binding with a novel partner.
To identify candidates for involvement in such an interaction, we have used yeast two-hybrid cDNA expression library screening (21). We have identified a number of interactors for huntingtin's N-terminus that suggest a variety of cellular processes to be explored. Most notably, a major class of proteins represented by three independent members implicates the WW domain, an ancient protein motif involved in non-receptor signaling, channel function, protein processing and pre-mRNA splicing, as a potential participant in huntingtin's inherent function and the pathogenesis of HD (22).
RESULTS
Isolation of huntingtin yeast partners (HYPs)
It has been proposed that altered huntingtin-protein interaction(s) are involved in HD pathogenesis (9-11,20). Consequently, we have surveyed this ~350 kDa protein using distinct yeast two-hybrid systems featuring LexA (23) or GAL4 (24) bipartite DNA binding-activation domains. We generated six bait clones that express part of huntingtin (Fig.
Figure 1. Huntingtin yeast two-hybrid strategy. The position of huntingtin's variable polyglutamine (Qn) and proline-rich (Pn) tracts and segments with either three or four HEAT repeats (HEAT) are depicted on a schematic diagram of the full-length, 3144 amino acid, protein (shaded bar) (accession no. L12392). The line below indicates the relative locations of the huntingtin fusion protein fragments comprising bait clones, pLexA-HD1-425Q62, pLexA-HD1434-1721 (open boxes), pGBT9-HD1-550 Q58, pGBT9-HD530-1050, pGBT9-HD1434-1721 and pGBT9-HD2226-3144 (filled boxes), used in LexA- and GAL4-based yeast two-hybrid cDNA library screens. The number of independent huntingtin interactors that each bait detected is given at the bottom. Table 1.
Bait clone
Huntingtin interactor
Identity
cDNA library
Accession no.;
reference
pLexA-HD1-425Q62
HYPA
mouse FBP-11
WW domains, pB42AD fetal brain
U40747; 26,
AFO49523
AF049524
AF049528
HYPB
novel; WW domain
pB42AD fetal brain
AF049610,
AF049103
HYPD
MAGE-3
pB42AD fetal brain
U03735; 32
HYPE
novel
pB42AD fetal brain
AF049611
HYPF
26S proteasome subunit P31
pB42AD fetal brain
P48556; 28
pGBT9-HD1-550 Q58
HYPA
mouse FBP-11 WW domains
pVP16 testis
U40747; 26
AF049523
HYPB
novel; WW domain
pVP16 testis
AF049610
HYPC
novel; WW domains
pVP16 testis
AF049525
HYPG
hE2-25K; HIP-2
pGAD10 fetal brain
P27924; 29
HYPH
novel; ankyrin repeats
pVP16 testis
AF049612
HYPI
symplekin
pVP16 testis
U88726; U49240; 30
HYPJ
mouse [alpha]-adaptin-C
pVP16 testis
B30111; 31
AF049527
HYPK
novel
pVP16 testis
AF049613
HYPL
novel
pVP16 testis
AF049614
HYPM
novel
pVP16 testis
AF049615
pGBT9-HD530-1050
-
pGAD10 fetal brain;
pVP16 testis
pLexA-HD1434-1721
-
pB42AD fetal brain
pGBT9-HD1434-1721
-
pGAD10 fetal brain;
pVP16 testis
pGBT9-HD2226-3144
-
pGAD10 fetal brain;
pVP16 testis
Surprisingly, despite robust expression (data not shown) and screening of >4 × 106 cDNAs, the internal and C-terminal baits comprising >70% of huntingtin yielded no interactor clones. This may indicate the lack of true interactor cDNAs in these libraries, failure of the bait polypeptides to assume native conformations or perhaps the inability of the bulk of huntingtin to participate in interactions with other proteins. In contrast, mutant N-terminal baits yielded 13 distinct HYPs, most represented by multiple independent cDNAs. Two, HYPA and HYPB, were also identified in screens of both the brain and testis cDNA libraries.
Description of huntingtin N-terminal interactors
To determine whether any of the HYPs encode previously described proteins that would implicate huntingtin in particular cellular processes, we searched DNA and protein databases (Table 1). Six of the HYPs represent known proteins associated with at least four different cellular pathways.
HYPA is the human homolog of mouse FBP-11, a formin-binding WW domain protein involved in spliceosome function (GenBank accession no. U40747) (26; M. Bedford, personal communication) that also exhibits extensive sequence identity to a predicted 84.7 kDa Caenorhabditis elegans WW domain protein, ZK1098.1 (accession no. P34600) and to two yeast proteins, Schizosaccharomyces pombe hypothetical protein Z98602 (accession no. S40923) and Saccharomyces cerevisiae splicing factor Prp40 (YKL012w; accession no. P33203) (27).
Two interactors, HYPF and HYPG, are involved in protein catabolism. HYPF is the 26S proteasome regulatory subunit P31, involved in the ATP-dependent degradation of ubiquitinated proteins (accession no. P48566) (28). HYPG, the UBC1 ubiquitin-conjugating enzyme hE2-25K (accession no. P27924) participates in the degradation of short-lived and misfolded proteins and has been reported previously as a huntingtin interactor (29).
HYPI and HYPJ are both proteins involved in the function of specialized membranes. HYPI, symplekin, is a protein at the cytoplasmic plaque face of certain tight junctions (accession no. U88726) (30) and is also found in the nucleoplasm. HYPJ, the human homolog of mouse [alpha]-adaptin-C (HYPJ) is a subunit of the plasma membrane adaptor assembly protein complex 2 in the coat surrounding the cytoplasmic face of coated vesicles (accession no. B30111) (31).
The other eight interactors have not been associated with particular functions, although one, HYPD, is the protein MAGE-3 (HYPD), a melanoma-associated antigen expressed in a variety of tumor cells (accession no. U03735) (32). Of the remaining seven, HYPE, HYPK, HYPL and HYPM display no significant DNA or amino acid homology to previously reported genes, while HYPB, HYPC and HYPH exhibit motifs that are found in a number of otherwise dissimilar proteins. Interestingly, HYPB and HYPC, like HYPA (FBP-11), possess related WW domains. HYPH displays homology with ankyrin repeats.
HYPA, HYPB and HYPC are members of a WW domain family
The fact that HYPA, HYPB and HYPC are related by shared motifs strongly suggests a role for a class of WW domain proteins in huntingtin's normal function and/or HD pathogenesis. We attempted to extend the cDNA sequences for these HYPs by cDNA screening and expressed sequence tag (EST) database searching.
The overlapping HYPA brain and testis cDNAs contain tandem WW domain-coding sequences and together encode an open reading frame (ORF) of 423 amino acids (accession nos AF049523 and AF049524). The additional analyses revealed two alternate versions of the protein, one with a 42 amino acid insert upstream of the WW domains (accession no. AF049528) and another possessing an 18 residue insert downstream of the WW domains (Fas ligand-associated factor 1, accession no. U70667). The EST database did not add any 5[prime] or 3[prime] sequence, but confirmed multiple splice versions of HYPA, suggesting isoforms of the protein that may each have a different biological activity.
The independent brain and testis HYPB cDNA clones selected in our yeast two-hybrid screens encode portions of the same 127 amino acid ORF and each contains a single WW domain (accession no. AF049610). EST searching revealed a large number of cDNAs, from a wide variety of tissue sources, with sequence identity to HYPB, but none of these showed evidence of alternative splice forms.
We selected a single HYPC cDNA in the two-hybrid screen (accession no. AF049525). This clone contains an ORF of 143 residues, predicting a novel polypeptide with two tandemly arrayed, WW domain-related sequences. Database searches revealed three human ESTs but these did not extend the sequence of our HYPC cDNA. Interestingly, one of these ESTs appears to represent a splice variant lacking the sequences encoding both WW domains and the intervening spacer, increasing the complexity of isoforms expected from this family.
HYPA, HYPB and HYPC are different proteins that share related WW domains (Fig.
Figure 2. HYPA, HYPB and HYPC WW domains are family members. The individual WW domains in HYPA, HYPB, HYPC and mouse YAP65 (accession no. X80508) are aligned to illustrate amino acid sequence identity with the first (shaded black) and second (shaded gray) WW domains of HYPA/FBP-11 (accession no. U40747). The conserved tryptophans and proline residue, shared by all WW domain family members, are at positions 6, 28 and 31, respectively. Members of the HYPA/FBP-11 subclass typically bind proline-rich segments containing PPLP and possess three conserved internal tyrosine residues (positions 17-19) (26,34). Each module is shown with five flanking amino acids. The tandem motifs in HYPA/FBP-11 and HYPC are separated by a 15 amino acid spacer that is also highly conserved (not shown). The prolines substituted in the variant HYPB WW domain in the pB42AD-HYPBW/F prey construct (Fig. 4) are at positions 31 and 36. Multiple domains in a given protein are numbered from the N-terminus of the protein. Alignments with MegAlign software (Lasergene, DNASTAR). To determine whether huntingtin's WW domain protein partners exhibit a broad expression pattern, like huntingtin itself, or a more restricted distribution consistent with the specific neuropathology of HD, we examined HYPA, HYPB and HYPC mRNA levels by northern blot analysis. The results, shown in Figure
To characterize precisely huntingtin's interaction with these WW domain proteins, we analyzed the two family members detected as multiple cDNAs in the yeast two-hybrid system. Figure To test the robustness of these interactions, we also reversed the bait-prey relationships and tested a different huntingtin N-terminal fragment. HYPA and HYPB DNA-binding domain fusion baits were assessed against preys with a longer (HD1-550) huntingtin segment containing either 23 or 62 glutamines. As shown in Figure These results are consistent with the nature of the WW domain as a modular protein-protein interaction motif (35). Consequently, we also asked whether these WW domain proteins can undergo homo- or heterotypic interactions, expressing each as an activation domain and a DNA-binding domain fusion protein (Fig. In these experiments, we also examined the self-association properties of huntingtin's N-terminus. Expression of pLexA-HD1-425Q2, Q23 or Q62 DNA-binding domain or pB42AD-HD1-550Q23 or Q62 activation domain fusion proteins, singly or together in any of the six possible bait-prey combinations, failed to yield interaction based on our stringent selection criteria (data not shown). Thus, regardless of polyglutamine length, these particular N-terminal fragments do not associate to form avid transcription complexes. Table 2. To determine whether huntingtin's WW domain protein interactors bind huntingtin via their related WW domains, we mutated HYPB's single WW domain motif, introducing codon changes that substitute phenylalanines for critical tryptophan residues (33). As shown in Figure WW domains normally bind via short proline-rich segments in their protein ligands (26). FBP-11 and YAP65, representing separate classes of WW domain proteins, associate preferentially with ligands possessing PPLP and PY motifs, respectively (33,34). Neither of these sequences is present in human huntingtin's N-terminal segment, although there is a proline-rich stretch following the glutamine tract. To delineate the portion of huntingtin's N-terminus responsible for WW domain binding, we used GST-HYP fusion proteins, including variants with distinct polyglutamine and proline-rich segments, to capture truncated huntingtin products expressed in COS7 cell extracts. HYPA, HYPB and HYPC each bind huntingtin with glutamine tracts of normal or disease-producing length (Fig. We next tested the adjacent proline-rich segment by removing the cognate sequences from the pcDNA3HD1-550Q2 construct. The modified polypeptide encoded by pcDNA3HD1-550Q2[Delta]P was detected by the anti-huntingtin antibody but was not captured by the GST-HYP fusion proteins, directly implicating huntingtin's proline-rich segment in these interactions. This target site shows specificity for a subset of WW domains, as it is captured by the tandem WW domain module of FBP-11 (identical to HYPA) but fails to bind to the analogous tandem WW domain module of mYAP65 fusion proteins (Fig. In these experiments, we also detect huntingtin degradation products of variable intensity whose mobility shifts due to the variable polyglutamine stretch parallel the expected bands (Fig. A physiological role for the WW domain partners in supporting the function of normal huntingtin or in triggering pathogenesis with mutant huntingtin would be most likely to result from an interaction with the native protein. As shown in Figure Huntingtin's primary sequence provides no obvious clues to its physiological role or to the biochemical disruption by which the HD mutation leads to specific neuronal degeneration. Consequently, we have sought clues to these processes via huntingtin's interactions with other proteins. Our data indicate that the normal and mutant versions of huntingtin's N-terminus are capable of many diverse interactions that implicate huntingtin in a variety of cellular processes that are candidates for huntingtin's normal and/or abnormal function. Huntingtin's N-terminus previously has been reported to associate in yeast two-hybrid assays with four proteins: HAP1 (36), a novel protein implicated in intracellular protein trafficking (37,38); HIP1 (39,40), a human homolog of yeast cytoskeletal protein Sla2p; CBS, the enzyme cystathionine [beta]-synthase (41); and HIP2, the hE2-25K ubiquitin-conjugating enzyme (HYPG) which is active in protein turnover (29). While our survey identified the latter protein, it also produced 12 new huntingtin-binding proteins, expanding considerably the scope of huntingtin's potential activities. Two of the new interactors, [alpha]-adaptin-C/HYPJ and the 26S proteasome regulatory subunit p31/HYPF, support previous proposals for huntingtin functioning in protein trafficking (37,38,42) and degradation (29). Two, HYPA (FBP-11) and HYPI (symplekin), suggest novel processes, mRNA splicing and tight junction function, respectively. However, for the majority of the interactors (HYPB, HYPC, HYPD, HYPE, HYPH, HYPK, HYPL and HYPM), more detailed characterization will be required to discover a functional role. Interestingly, HYPA (FBP-11) and HYPI (symplekin) are both detected in the cytoplasm as well as in the nucleus (L. Passani and M. MacDonald, unpublished data; 30), although their activities have been studied in one location. This suggests that these HYPs may have additional, as yet unrecognized activities. Interaction with such `dual residence' partners implies that huntingtin's normal function may involve multiple intracellular addresses. This is consistent with reports that while huntingtin is mainly a cytoplasmic protein, a small fraction may be found in the nucleus (43). This abundance of N-terminal huntingtin interactors contrasts dramatically with the absence of cloned binding partners for the remainder of the protein. We uncovered no cDNA partners for huntingtin's highly conserved C-terminus or for two internal fragments that possess tandemly arrayed HEAT repeats (25), motifs that have been implicated in interactions between other proteins. Our results suggest that identification of binding partners for the C-terminal two-thirds of huntingtin will probably require alternative strategies to yeast two-hybrid screening. Despite the lack of interactors for the bulk of the protein, huntingtin's N-terminal interactors provide a wealth of candidates that warrant further evaluation. Most obvious is the class of WW domain interactors represented by HYPA, HYPB and HYPC. WW domain proteins are currently the subjects of intense investigation as they have been found to play critical roles in a number of cellular processes (44). For example, YAP65 binds to the SH3 domain of the Yes non-receptor kinase, connecting it to intracellular signaling (45). NEDD4 is a ubiquitin-protein ligase implicated in reduced activity of the amiloride-sensitive epithelial sodium channel (46). Interestingly, mutations of the channel's PPPNY target sequence abolish binding of NEDD4's WW domains and thereby cause Liddle syndrome, an inherited form of hypertension (47). The WW domain of neural protein FE65 interacts with Mena, the mammalian homolog of Drosophila Enabled, a cytoskeletal protein involved in microfilament assembly (48). FE65 also interacts via its non-WW domain region with the amyloid precursor protein (APP) central to the development of Alzheimer disease (49). WW domains are also found in proteins implicated in Ras or MAP kinase signaling pathways and in ligands that bind to transcription factors, RNA polymerase II, the dystrophin-associated b-dystroglycan receptor and formin (22,44). Notably, a class of WW domain proteins containing hect motifs interacts with atrophin-1, the defective protein in dentatorubral and pallidoluysian atrophy (DRPLA), another dominantly inherited CAG repeat expansion disorder (50). Members of the HYPA/FBP-11 WW domain class form a distinct subclass that favors a ligand containing a PXXXPPLP target sequence (26,34). Several close variants of this target site are found in human huntingtin's proline-rich N-terminus, including PXXXPPXP motifs similar to a segment in the FBP-11 WW domain ligand WBP-10 (34). This particular target sequence is also recognized by the SH3 domains of abl, src and fyn (34), suggesting that huntingtin's N-terminus may also bind SH3 domain proteins. This possibility is supported both by a report of huntingtin's SH3-dependent association with epidermal growth factor (EGF) receptor signaling complexes (51) and by our isolation of SH3P12, a mouse SH3 domain peptide ligand (52), using huntingtin N-terminal baits to screen a mouse embryo interaction cDNA library (C. Dompe and M. MacDonald, unpublished data). The HYPs also present a number of new entrees into the exploration of HD pathogenesis, including both previously suggested pathways, such as vesicle transport and huntingtin degradation, and new directions involving membrane, nuclear and cytoskeletal functions. Although none of the HYPs exhibits a striking difference in binding to normal and mutant huntingtin, subtle differences, consistent with the late onset and long duration of the disorder, were evident in the yeast two-hybrid assays. Several scenarios are possible with any huntingtin interactor: (i) a change in binding could, over time, cause the gradual loss of a huntingtin activity or an activity of the interactor, assuming that these are crucial for neuronal cell survival; (ii) an aberrant association could cause an increase in activity of either huntingtin or the interactor with potential toxic consequences; and (iii) an altered interaction might have an indirect consequence, such as promoting the formation of insoluble aggregates that are capable of killing target neurons independently of any coincident effect on huntingtin or interactor activity. The diversity of the proteins that interact with huntingtin's N-terminus broadens the options for investigation of the selective neuronal cell loss in HD under any of these three hypotheses. Moreover, the discovery of a class of WW domain interactors suggests a number of specific functions, such as pre-mRNA splicing, to be explored in HD brain and model systems. Huntingtin yeast two-hybrid, Escherichia coli and mammalian clone constructs were generated using restriction fragments and PCR products from pBS-HD1-3144Q23 and pBS-HD1-3144Q62. These encode full-length huntingtin with 23 and 62 glutamines, respectively, and were assembled in pBluescriptII (Stratagene) from partial HD cDNAs (3; accession no. L12392, 343-10 200 bp) and a 5[prime] exon 1 HD genomic fragment (196-343 bp). Huntingtin expression constructs were created in pLexA (pJG4-5; 53,54), pGBT9 (accession no. U07646, Clontech), pB42AD (pJG4-5; 53,54), pGEX-2TK (Pharmacia) and pcDNA3FLAG, a modified pcDNA3 (Invitrogen) vector kindly provided by Dr V. Ramesh. In all cases, the clones were validated by DNA sequencing (55) and by SDS-PAGE gel analysis of protein products synthesized in a coupled in vitro transcription/translation reaction (TNT; Amersham). Huntingtin bait clones pLexA-HD1-425Q2, pLexA-HD1-425Q23 and pLexA-HD1-425Q62 encode residues 1-425 (T388P) with two, 23 and 62 glutamines, respectively, while baits pGBT9-HD1-550Q23 and pGBT9-HD1-550Q58 and preys pB42AD-HD1-550Q23 and pB42AD-HD1-550Q62 encode huntingtin amino acids 1-550 with either 23, 58 or 62 glutamines. Huntingtin bait pLexA-HD1-3144Q23 encodes full-length huntingtin with 23 glutamines. Internal bait pGBT9-HD530-1050 expresses huntingtin amino acids 530-1050, whereas baits pLexA-HD1434-1721 and pGBT9-HD1434 encode huntingtin residues 1434-1721. The C-terminal huntingtin bait pGBT9-HD2226-3144 comprises amino acids 2226-3144. Mammalian expression constructs pcDNA3-FLAGHD1-550Q23 and pcDNA3- FLAGHD1-550Q62 produce 5[prime] FLAG-tagged huntingtin N-terminal fusion proteins (residues 1-550) with 23 and 62 glutamines, respectively. pcDNA3FLAG-HD1-550Q2 and pcDNA3FLAG-HD1-550Q2[Delta]P express variant N-terminal fragments with two glutamines, plus or minus the adjacent proline-rich segment (436-546 bp). Note that the number of consecutive glutamines in each construct is greater by two than the number of CAG repeats, due to the CAACAG codons that follow the CAG tract (3). Baits pLexA-HYPA and pLexA-HYPB were generated using the entire HYPA and HYPB cDNA insert, respectively. pB42AD-HYPBW/F encodes a HYPB fusion protein with tryptophan to phenylalanine substitutions (W31F; W36F) created by PCR-based site-specific mutagenesis. pB42AD-HYPB-WW encodes HYPB's single WW domain (residues 1-57). The E.coli expression constructs encoding GST-HYPA, GST-HYPB and GST-HYPC fusion proteins were generated from HYP cDNAs. GST-HYPA1-146 expresses HYPA residues 1-146. pGEX-2TK-FBP-11 WW and pGEX-2TK-mYAP65 WW encode GST-FBP-11 and GST-YAP65 isolated tandem WW domain fusion proteins, respectively (34), and were kindly provided by Drs M. Bedford and P. Leder. The pLexA-APP38-377 and pB42ADCl 3.9 bait-prey combination, encoding a LexA-APP fusion protein and a positive yeast two-hybrid interactor, respectively, were a gift of Drs S. Guenette and R. Tanzi. Other non-huntingtin bait controls were pRFHM1 (23) and pLexA-TBP1-104Q38, which produces a LexA-TATA-binding protein (TBP) fusion protein with 38 glutamine residues. The non-huntingtin control pGBT9 bait-prey plasmid combinations for the GAL4 system were pVA3 and pTD1 (Clontech). General yeast two-hybrid methods have been described previously (57). Yeast hosts were EGY48 (MAT[alpha] his3 leu2::3Lexop-LEU2 ura3 trp1 LYS2) (22,47,48) (LexA) and MAV103 (MATa ura3-52 leu2-3 URA3:: SPAL10-URA3-112 trp1-901 his3[Delta]200 ade2-101 GAL4 [Delta] gal80 [Delta]can1R cyh2R LYS2::GAL1-HIS3 GAL1-lacZ) (56) (GAL4). Screens of a human fetal brain frontal cortex cDNA library in pB42AD (provided by Drs D. Krainc and R. Brent) (LexA), a human fetal brain library in pGAD10 (Clontech) or a human testis library in pVP16 (Drs K. Tashiro and I. Verma) (GAL4) were performed as described (23,53,54,56). Primary transformants were selected by growth for 3-5 days at 30°C on medium lacking uracil, histidine, tryptophan and leucine in the presence of galactose (LexA) or, for the other system, media with 75 mM 3-amino-triazole and glucose in the absence of histidine, tryptophan and leucine, followed by growth on glucose plates lacking uracil, tryptophan and leucine (GAL4). Primary transformants were then tested for [beta]-galactosidase activity using a filter assay for the conversion of Xgal for 1 (LexA) or 6-8 (GAL4) h. cDNA inserts in doubly (Lex) or triply (GAL4) positive transformants were obtained by PCR amplification and characterized and grouped into classes by restriction enzyme and Southern blot analyses. Unique cDNA plasmids were shuttled into E.coli, purified and sequenced by dideoxy chain termination (55). The interaction properties of the longest purified interactor cDNA in each class were tested for activation of reporter genes using huntingtin (pLexA-HD1-425Q2, Q23 and Q62; pGBT9HD1-550Q23 and Q62) and non-huntingtin (pRFHM, pEG202-TBP1-104Q38, pVA3) baits. [beta]-Galactosidase reaction product was measured as described (Clontech Matchmaker) using the formula: [beta]-galactosidase units = 1000 × (OD420/t × V × OD600) where t = incubation time (minutes) and V = volume (ml) of culture. Statistical analysis software was SigmaStat (Jandel Scientific). GST fusion proteins were expressed from pGEX-2TK constructs in BL21(DE3)pLysE by induction with isopropyl-[beta]-d-thiogalactopyranoside (IPTG): GST, GST-HYPB and GST-FBP-11 WW with 0.3 mM IPTG for 2 h at 37°C; GST-HYPA and GST-mYAP65 with 0.03 mM IPTG for 30 min at 37°C; and GST-HYPC with 0.03 mM IPTG for 5-6 h at room temperature. The GST fusion proteins in cleared E.coli sonicates were bound to glutathione-Sepharose 4B beads (Pharmacia) by incubation in binding buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 0.5% NP-40, 2.5 mM MgCl2, 2.5 mM KCl, 1.5 mM CaCl2) for 30 min at 4°C. Mammalian cell extracts (at ~10 mg/ml) were prepared as described (16,17) from immortalized lymphoblastoid cells established previously from normal and HD individuals genotyped for the HD CAG repeat (3,16) and from COS7 cells 48 h after transfection. Proteins were captured by GST fusions by incubating lymphoblastoid and COS7 cell extracts (~500 µg) with ~1 µg of washed GST fusion protein-Sepharose beads in 300 µl of binding buffer for 1 h at 4°C. Washed bound beads (binding buffer containing 3% NP-40) were boiled in SDS-PAGE sample buffer to release captured proteins. Immunoprecipation of full-length and truncated huntingtin was accomplished using HF-1, a polyclonal anti-huntingtin antisera as described previously (16,17). Protein complexes from GST fusion protein and immunoprecipitation assays were displayed by electrophoresis on 5 or 7% SDS-PAGE gels and transferred to nitrocellulose by electroblotting. Immunoblots were probed with the anti-huntingtin antibody mAb number 2166 (Chemicon) using enhanced chemiluminescence detection (ECL; Amersham). Protein concentration was determined by modified Bradford assay (Bio-Rad). Multiple human adult and fetal tissue northern blots (~1 µg of mRNA per lane) (Clontech) were hybridized with 32P-labeled HYPA-, HYPB- and HYPC-specific cDNA probes corresponding to bp 834-1253 (accession no. AF049523), bp 164-883 (accession no. AF049610) and bp 1-197 (accession no. AF049525), respectively. Probes were labeled with [32P]dATP using random oligonucleotide priming as described previously (58). Blots were exposed to X-ray film for 16 (HYPA, HYPB) and 64 (HYPC) h. DNA, protein and EST database searches were performed using BLAST 2.0 programs (59) including Basic BLAST on the NCBI server. HYPA AF049523, AF049524, AF049528; HYPB AF049610, AF049103; HYPC AF049525; HYPE AF049611; HYPH AF049612; HYPI AF049526; HYPJ AF049527; HYPK AF049613; HYPL AF049614; HYPM AF049615. We thank Drs K. Tashiro, I. Verma, R. Bernards, D. Krainc, R. Brent, S. Guennette, R. Tanzi, S. Lockwood, V. Ramesh and M. Timmers for cDNA libraries and plasmids. Dr A. Murthy's help with initial experiments was invaluable. We are grateful to Drs M. Bedford and P. Leder for providing plasmids and for sharing results before publication. Supported by NIH grants NS32765 and NS16367, the Foundation for the Care and Cure of Huntington's Disease, the Hereditary Disease Foundation and the Huntington's Disease Society of America Coalition for the Cure. P.W.F. was a recipient of a Human Frontiers Program Long Term Fellowship.
Expression of HYPA, HYPB and HYPC
Figure 3. Northern blot analysis of HYPA, HYPB and HYPC. The pattern of HYPA- (A), HYPB- (B) and HYPC- (C) specific hybridization to northern blots of mRNA from adult and fetal human tissues is shown. Tissues are given above each lane: peripheral blood leukocytes (Lc), colon (C), ileum (I), ovary (O), testis (T), prostate (P), thymus (Th), spleen (S), pancreas (Ps), kidney (K), skeletal muscle (Sm), liver (L), lung (Lu), placenta (Pl), brain (B), heart (H), fetal kidney (fK), fetal liver (fL), fetal lung (fLu), fetal brain (fB). Thymus mRNA appears to be degraded. (C) was exposed four times longer than (A) and (B), and signals in all tissues except thymus could be detected by yet longer exposures. The molecular weight markers to the left refer to the adult blots and those to the right to the fetal blot.
A

B

C

Interaction of HYPA and HYPB with huntingtin in the yeast two-hybrid system
Bait clone
Prey clone
pB42AD (n = 6)
pB42AD-HYPA (n = 12)
PB42AD-HYPB (n = 14)
pLexA-HD1-425Q2
3.1 ± 1.3
55.3 ± 3.3a
363.2 ± 19.0a
pLexA-HD1-425Q23
2.0 ± 1.0
118.1 ± 8.4a
524.3 ± 19.3a
pLexA-HD1-425Q62
3.5 ± 1.6
220.8 ± 1.6a
626.5 ± 34.4a
WW domain HYPs interact via huntingtin's N-terminal proline-rich segment
Figure 4. Yeast two-hybrid analyses of HYPA and HYPB. (A) The interaction of HYPA, HYPB and HYPC preys and huntingtin baits possessing different glutamine lengths. LEU2 and LacZ reporter gene activation by HYPA (pB42AD-HYPA) and HYPB (pB42AD-HYPB) preys in combination with N-terminal (pLexA-HD1-425Q2 and Q62) and full-length huntingtin (pLexA-HD1-3144Q23) baits is shown by growth on selection medium and [beta]-galactosidase assay, respectively. (B) The interaction of huntingtin preys with HYPA and HYPB baits and HYPA and HYPB self-association. LEU2 and LacZ reporter gene activation by HYPA (pB42AD-HYPA), HYPB (pB42AD-HYPB) and huntingtin N-terminal (pB42AD-HD1-550Q23 and Q62) preys with HYPA (pLexA-HYPA) and HYPB (pLexA-HYPB) baits is assessed by growth on selection plates and [beta]-galactosidase assay, respectively. (C) The interactions of huntingtin baits with variant HYPB WW domain preys. LEU2 and LacZ reporter gene activation by wild-type (pB42AD-HYPB) or mutant (pB42AD-HYPBW/F) WW domain HYPB preys, and the isolated HYPB WW domain (pB42AD-HYPB-WW) prey in combination with N-terminal (pLexA-HD1-425Q2-Q62) and full-length huntingtin (pLexA-HD1-3144Q23) baits in shown. The interaction of these preys with a HYPB (pLexA-HYPB) bait demonstrates self-association properties of HYPB. A non-huntingtin bait-prey control combination (pLexA-APP38-377 and pB42AD-Cl3.9) is shown in all panels.
A

B

C

WW domain partners bind to huntingtin in HD lymphoblastoid cells
DISCUSSION
Figure 5. HYPA, HYPB and HYPC binding to huntingtin's N-terminus in COS7 cell extracts. The immunoblot in (A) shows the detection of huntingtin N-terminal fragments with anti-huntingtin antibody number 2166 in protein complexes isolated from transfected COS7 cell extracts by immobilized anti-huntingtin antibody HP1 (16,17), GST, GST-HYPA and GST-HYPB. (B) Results for HYPC (GST-HYPC) and tandem FBP-11 (GST-FBP-11 WW) and YAP65 (GST-YAP WW) WW domain module fusion proteins. The length of the glutamine tract, 2, 23 and 62 residues (Q2, Q23, Q62), or absence of the proline-rich stretch (Q2[Delta]P) in the huntingtin N-terminal fragments is given above each lane. The position of the molecular weight standard in kilodaltons (kDa) is indicated.
A

B

Figure 6. HYPA, HYPB and HYPC binding to huntingtin in normal and HD patient lymphoblastoid cell extracts. The immunoblots in (A) and (B) show detection by anti-huntingtin antibody of full-length endogenous normal (~350 kDa) and mutant (>350 kDa) huntingtin with the different polyglutamine lengths encoded by the polymorphic HD CAG repeat (CAGn) indicated above each lane. Proteins from lymphoblastoid extracts (Input) were bound specifically by immobilized GST, GST-HYPA1-416, GST-HYPC, GST-FBP-11 WW and GST-YAP65 (A) or from GST-HYPB (B). A single lane of GST-HYPB-bound proteins is shown in (A) for comparison. Normal individuals are (CAG 22/18), HD heterozygotes (CAG 39/20, 70/19, 86/20, 86/22) and HD homozygotes (CAG 48/40, 54/41).
A

B

MATERIALS AND METHODS
HD expression constructs
HYP expression clones
Control plasmids
Yeast two-hybrid screens
Protein extracts, invitro binding, immunoprecipitation and immunoblot analyses
Northern analysis
Accession numbers
ACKNOWLEDGEMENTS
REFERENCES
This article has been cited by other articles:
This page is run by Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, as part of the OUP Journals
Comments and feedback: www-admin{at}oup.co.uk
Last modification: 12 Aug 1998
Copyright©Oxford University Press, 1998.
![]()
CiteULike
Connotea
Del.icio.us What's this?
![]()
![]()

![]()
![]()
![]()
A. L. Southwell, A. Khoshnan, D. E. Dunn, C. W. Bugg, D. C. Lo, and P. H. Patterson
Intrabodies Binding the Proline-Rich Domains of Mutant Huntingtin Increase Its Turnover and Reduce Neurotoxicity
J. Neurosci.,
September 3, 2008;
28(36):
9013 - 9020.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
S. Raychaudhuri, M. Sinha, D. Mukhopadhyay, and N. P. Bhattacharyya
HYPK, a Huntingtin interacting protein, reduces aggregates and apoptosis induced by N-terminal Huntingtin with 40 glutamines in Neuro2a cells and exhibits chaperone-like activity
Hum. Mol. Genet.,
January 15, 2008;
17(2):
240 - 255.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
A. L. Lumsden, T. L. Henshall, S. Dayan, M. T. Lardelli, and R. I. Richards
Huntingtin-deficient zebrafish exhibit defects in iron utilization and development
Hum. Mol. Genet.,
August 15, 2007;
16(16):
1905 - 1920.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
J. T. Wang, N. J. Kunzevitzky, J. C. Dugas, M. Cameron, B. A. Barres, and J. L. Goldberg
Disease Gene Candidates Revealed by Expression Profiling of Retinal Ganglion Cell Development
J. Neurosci.,
August 8, 2007;
27(32):
8593 - 8603.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
A. N.T. Strehlow, J. Z. Li, and R. M. Myers
Wild-type huntingtin participates in protein trafficking between the Golgi and the extracellular space
Hum. Mol. Genet.,
February 15, 2007;
16(4):
391 - 409.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Y. Kato, T. Miyakawa, J.-i. Kurita, and M. Tanokura
Structure of FBP11 WW1-PL Ligand Complex Reveals the Mechanism of Proline-rich Ligand Recognition by Group II/III WW Domains
J. Biol. Chem.,
December 29, 2006;
281(52):
40321 - 40329.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
B. Dehay and A. Bertolotti
Critical Role of the Proline-rich Region in Huntingtin for Aggregation and Cytotoxicity in Yeast
J. Biol. Chem.,
November 24, 2006;
281(47):
35608 - 35615.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
J.-i. Takeda, Y. Suzuki, M. Nakao, R. A. Barrero, K. O. Koyanagi, L. Jin, C. Motono, H. Hata, T. Isogai, K. Nagai, et al.
Large-scale identification and characterization of alternative splicing variants of human gene transcripts using 56 419 completely sequenced and manually annotated full-length cDNAs
Nucleic Acids Res.,
September 1, 2006;
34(14):
3917 - 3928.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
N. De Marco, M. Buono, F. Troise, and G. Diez-Roux
Optineurin Increases Cell Survival and Translocates to the Nucleus in a Rab8-dependent Manner upon an Apoptotic Stimulus
J. Biol. Chem.,
June 9, 2006;
281(23):
16147 - 16156.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. Li, H. P. Phatnani, Z. Guan, H. Sage, A. L. Greenleaf, and P. Zhou
Solution structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction with the hyperphosphorylated C-terminal domain of Rpb1
PNAS,
December 6, 2005;
102(49):
17636 - 17641.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
X.-J. Sun, J. Wei, X.-Y. Wu, M. Hu, L. Wang, H.-H. Wang, Q.-H. Zhang, S.-J. Chen, Q.-H. Huang, and Z. Chen
Identification and Characterization of a Novel Human Histone H3 Lysine 36-specific Methyltransferase
J. Biol. Chem.,
October 21, 2005;
280(42):
35261 - 35271.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
P. H. Anborgh, C. Godin, M. Pampillo, G. K. Dhami, L. B. Dale, S. P. Cregan, R. Truant, and S. S. G. Ferguson
Inhibition of Metabotropic Glutamate Receptor Signaling by the Huntingtin-binding Protein Optineurin
J. Biol. Chem.,
October 14, 2005;
280(41):
34840 - 34848.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. Ralser, U. Nonhoff, M. Albrecht, T. Lengauer, E. E. Wanker, H. Lehrach, and S. Krobitsch
Ataxin-2 and huntingtin interact with endophilin-A complexes to function in plastin-associated pathways
Hum. Mol. Genet.,
October 1, 2005;
14(19):
2893 - 2909.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
R. J. Ingham, K. Colwill, C. Howard, S. Dettwiler, C. S. H. Lim, J. Yu, K. Hersi, J. Raaijmakers, G. Gish, G. Mbamalu, et al.
WW Domains Provide a Platform for the Assembly of Multiprotein Networks
Mol. Cell. Biol.,
August 15, 2005;
25(16):
7092 - 7106.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
H. Otto, C. Conz, P. Maier, T. Wolfle, C. K. Suzuki, P. Jeno, P. Rucknagel, J. Stahl, and S. Rospert
The chaperones MPP11 and Hsp70L1 form the mammalian ribosome-associated complex
PNAS,
July 19, 2005;
102(29):
10064 - 10069.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
D. A. Sahlender, R. C. Roberts, S. D. Arden, G. Spudich, M. J. Taylor, J. P. Luzio, J. Kendrick-Jones, and F. Buss
Optineurin links myosin VI to the Golgi complex and is involved in Golgi organization and exocytosis
J. Cell Biol.,
April 25, 2005;
169(2):
285 - 295.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
T. Funayama, K. Ishikawa, Y. Ohtake, T. Tanino, D. Kurosaka, I. Kimura, K. Suzuki, H. Ideta, K. Nakamoto, N. Yasuda, et al.
Variants in Optineurin Gene and Their Association with Tumor Necrosis Factor-{alpha} Polymorphisms in Japanese Patients with Glaucoma
Invest. Ophthalmol. Vis. Sci.,
December 1, 2004;
45(12):
4359 - 4367.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
C. M. Everett and N. W. Wood
Trinucleotide repeats and neurodegenerative disease
Brain,
November 1, 2004;
127(11):
2385 - 2405.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
A. Khoshnan, J. Ko, E. E. Watkin, L. A. Paige, P. H. Reinhart, and P. H. Patterson
Activation of the I{kappa}B Kinase Complex and Nuclear Factor-{kappa}B Contributes to Mutant Huntingtin Neurotoxicity
J. Neurosci.,
September 15, 2004;
24(37):
7999 - 8008.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Y. Kato, K. Nagata, M. Takahashi, L. Lian, J. J. Herrero, M. Sudol, and M. Tanokura
Common Mechanism of Ligand Recognition by Group II/III WW Domains: REDEFINING THEIR FUNCTIONAL CLASSIFICATION
J. Biol. Chem.,
July 23, 2004;
279(30):
31833 - 31841.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
F. Colland, X. Jacq, V. Trouplin, C. Mougin, C. Groizeleau, A. Hamburger, A. Meil, J. Wojcik, P. Legrain, and J.-M. Gauthier
Functional Proteomics Mapping of a Human Signaling Pathway
Genome Res.,
July 1, 2004;
14(7):
1324 - 1332.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Z.-H. Qin, Y. Wang, E. Sapp, B. Cuiffo, E. Wanker, M. R. Hayden, K. B. Kegel, N. Aronin, and M. DiFiglia
Huntingtin Bodies Sequester Vesicle-Associated Proteins by a Polyproline-Dependent Interaction
J. Neurosci.,
January 7, 2004;
24(1):
269 - 281.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
E. Trushina, M. P. Heldebrant, C. M. Perez-Terzic, R. Bortolon, I. V. Kovtun, J. D. Badger II, A. Terzic, A. Estevez, A. J. Windebank, R. B. Dyer, et al.
Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease
PNAS,
October 14, 2003;
100(21):
12171 - 12176.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Y. F. Leung, B. J. Fan, D. S. C. Lam, W. S. Lee, P. O. S. Tam, J. K. H. Chua, C. C. Y. Tham, J. S. M. Lai, D. S. P. Fan, and C. P. Pang
Different Optineurin Mutation Pattern in Primary Open-Angle Glaucoma
Invest. Ophthalmol. Vis. Sci.,
September 1, 2003;
44(9):
3880 - 3884.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
J. Xia, D. H. Lee, J. Taylor, M. Vandelft, and R. Truant
Huntingtin contains a highly conserved nuclear export signal
Hum. Mol. Genet.,
June 15, 2003;
12(12):
1393 - 1403.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
S. Holbert, A. Dedeoglu, S. Humbert, F. Saudou, R. J. Ferrante, and C. Neri
Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease
PNAS,
March 4, 2003;
100(5):
2712 - 2717.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
S. Gines, I. S. Seong, E. Fossale, E. Ivanova, F. Trettel, J. F. Gusella, V. C. Wheeler, F. Persichetti, and M. E. MacDonald
Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice
Hum. Mol. Genet.,
March 1, 2003;
12(5):
497 - 508.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
P. W. Faber, C. Voisine, D. C. King, E. A. Bates, and A. C. Hart
Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity
PNAS,
December 24, 2002;
99(26):
17131 - 17136.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
R. R. Singaraja, S. Hadano, M. Metzler, S. Givan, C. L. Wellington, S. Warby, A. Yanai, C.-A. Gutekunst, B. R. Leavitt, H. Yi, et al.
HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis
Hum. Mol. Genet.,
November 1, 2002;
11(23):
2815 - 2828.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
E. Fossale, V. C. Wheeler, V. Vrbanac, L.-A. Lebel, A. Teed, J. S. Mysore, J. F. Gusella, M. E. MacDonald, and F. Persichetti
Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice
Hum. Mol. Genet.,
September 15, 2002;
11(19):
2233 - 2241.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. J. Bennett, K. E. Huey-Tubman, A. B. Herr, A. P. West Jr., S. A. Ross, and P. J. Bjorkman
Inaugural Article: A linear lattice model for polyglutamine in CAG-expansion diseases
PNAS,
September 3, 2002;
99(18):
11634 - 11639.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
V. Legendre-Guillemin, M. Metzler, M. Charbonneau, L. Gan, V. Chopra, J. Philie, M. R. Hayden, and P. S. McPherson
HIP1 and HIP12 Display Differential Binding to F-actin, AP2, and Clathrin. IDENTIFICATION OF A NOVEL INTERACTION WITH CLATHRIN LIGHT CHAIN
J. Biol. Chem.,
May 24, 2002;
277(22):
19897 - 19904.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
D. Hofreuter and R. Haas
Characterization of Two Cryptic Helicobacter pylori Plasmids: a Putative Source for Horizontal Gene Transfer and Gene Shuffling
J. Bacteriol.,
May 15, 2002;
184(10):
2755 - 2766.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Y. Kato, M. Ito, K. Kawai, K. Nagata, and M. Tanokura
Determinants of Ligand Specificity in Groups I and IV WW Domains as Studied by Surface Plasmon Resonance and Model Building
J. Biol. Chem.,
March 15, 2002;
277(12):
10173 - 10177.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
K. B. Kegel, A. R. Meloni, Y. Yi, Y. J. Kim, E. Doyle, B. G. Cuiffo, E. Sapp, Y. Wang, Z.-H. Qin, J. D. Chen, et al.
Huntingtin Is Present in the Nucleus, Interacts with the Transcriptional Corepressor C-terminal Binding Protein, and Represses Transcription
J. Biol. Chem.,
February 22, 2002;
277(9):
7466 - 7476.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
A. Khoshnan, J. Ko, and P. H. Patterson
Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity
PNAS,
January 22, 2002;
99(2):
1002 - 1007.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
S. K. Mishra, N. R. Agostinelli, T. J. Brett, I. Mizukami, T. S. Ross, and L. M. Traub
Clathrin- and AP-2-binding Sites in HIP1 Uncover a General Assembly Role for Endocytic Accessory Proteins
J. Biol. Chem.,
November 30, 2001;
276(49):
46230 - 46236.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Y. J. Kim, Y. Yi, E. Sapp, Y. Wang, B. Cuiffo, K. B. Kegel, Z.-H. Qin, N. Aronin, and M. DiFiglia
Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis
PNAS,
October 23, 2001;
98(22):
12784 - 12789.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
K. Sathasivam, B. Woodman, A. Mahal, F. Bertaux, E. E. Wanker, D. T. Shima, and G. P. Bates
Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients
Hum. Mol. Genet.,
October 1, 2001;
10(21):
2425 - 2435.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. Boehm and J. S. Bonifacino
Adaptins. The Final Recount
Mol. Biol. Cell,
October 1, 2001;
12(10):
2907 - 2920.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
A.-S. Lebre, L. Jamot, J. Takahashi, N. Spassky, C. Leprince, N. Ravise, C. Zander, H. Fujigasaki, P. Kussel-Andermann, C. Duyckaerts, et al.
Ataxin-7 interacts with a Cbl-associated protein that it recruits into neuronal intranuclear inclusions
Hum. Mol. Genet.,
May 1, 2001;
10(11):
1201 - 1213.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
S. Holbert, I. Denghien, T. Kiechle, A. Rosenblatt, C. Wellington, M. R. Hayden, R. L. Margolis, C. A. Ross, J. Dausset, R. J. Ferrante, et al.
The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis
PNAS,
January 24, 2001;
(2001)
41566798.
[Abstract]
[Full Text]
![]()
![]()
![]()

![]()
![]()
![]()
P. Hilditch-Maguire, F. Trettel, L. A. Passani, A. Auerbach, F. Persichetti, and M. E. MacDonald
Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles
Hum. Mol. Genet.,
November 1, 2000;
9(19):
2789 - 2797.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
F. Trettel, D. Rigamonti, P. Hilditch-Maguire, V. C. Wheeler, A. H. Sharp, F. Persichetti, E. Cattaneo, and M. E. MacDonald
Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells
Hum. Mol. Genet.,
November 1, 2000;
9(19):
2799 - 2809.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
K. B. Kegel, M. Kim, E. Sapp, C. McIntyre, J. G. Castano, N. Aronin, and M. DiFiglia
Huntingtin Expression Stimulates Endosomal-Lysosomal Activity, Endosome Tubulation, and Autophagy
J. Neurosci.,
October 1, 2000;
20(19):
7268 - 7278.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
L. A. Passani, M. T. Bedford, P. W. Faber, K. M. McGinnis, A. H. Sharp, J. F. Gusella, J.-P. Vonsattel, and M. E. MacDonald
Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis
Hum. Mol. Genet.,
September 1, 2000;
9(14):
2175 - 2182.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
J. D. Davidson, B. Riley, E. N. Burright, L. A. Duvick, H. Y. Zoghbi, and H. T. Orr
Identification and characterization of an ataxin-1-interacting protein: A1Up, a ubiquitin-like nuclear protein
Hum. Mol. Genet.,
September 1, 2000;
9(15):
2305 - 2312.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
N. R. Jana, M. Tanaka, G.-h. Wang, and N. Nukina
Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity
Hum. Mol. Genet.,
August 12, 2000;
9(13):
2009 - 2018.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
R. Luthi-Carter, A. Strand, N. L. Peters, S. M. Solano, Z. R. Hollingsworth, A. S. Menon, A. S. Frey, B. S. Spektor, E. B. Penney, G. Schilling, et al.
Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
Hum. Mol. Genet.,
May 22, 2000;
9(9):
1259 - 1271.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
H. Shibata, D. P. Huynh, and S.-M. Pulst
A novel protein with RNA-binding motifs interacts with ataxin-2
Hum. Mol. Genet.,
May 22, 2000;
9(9):
1303 - 1313.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. T. Bedford, D. Sarbassova, J. Xu, P. Leder, and M. B. Yaffe
A Novel Pro-Arg Motif Recognized by WW Domains
J. Biol. Chem.,
March 31, 2000;
275(14):
10359 - 10369.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Y. Nagai, T. Tucker, H. Ren, D. J. Kenan, B. S. Henderson, J. D. Keene, W. J. Strittmatter, and J. R. Burke
Inhibition of Polyglutamine Protein Aggregation and Cell Death by Novel Peptides Identified by Phage Display Screening
J. Biol. Chem.,
March 31, 2000;
275(14):
10437 - 10442.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Y. Takagaki and J. L. Manley
Complex Protein Interactions within the Human Polyadenylation Machinery Identify a Novel Component
Mol. Cell. Biol.,
March 1, 2000;
20(5):
1515 - 1525.
[Abstract]
[Full Text]
![]()
![]()
![]()

![]()
![]()
![]()
M. Metzler, C. D. Helgason, I. Dragatsis, T. Zhang, L. Gan, N. Pineault, S. O. Zeitlin, R. K. Humphries, and M. R. Hayden
Huntingtin is required for normal hematopoiesis
Hum. Mol. Genet.,
February 12, 2000;
9(3):
387 - 394.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
B. K. KAY, M. P. WILLIAMSON, and M. SUDOL
The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains
FASEB J,
February 1, 2000;
14(2):
231 - 241.
[Abstract]
[Full Text]
![]()
![]()
![]()

![]()
![]()
![]()
J. M. Boutell, P. Thomas, J. W. Neal, V. J. Weston, J. Duce, P. S. Harper, and A. L. Jones
Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin
Hum. Mol. Genet.,
September 1, 1999;
8(9):
1647 - 1655.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. Cornell, D. A. P. Evans, R. Mann, M. Fostier, M. Flasza, M. Monthatong, S. Artavanis-Tsakonas, and M. Baron
The Drosophila melanogaster Suppressor of deltex Gene, a Regulator of the Notch Receptor Signaling Pathway, Is an E3 Class Ubiquitin Ligase
Genetics,
June 1, 1999;
152(2):
567 - 576.
[Abstract]
[Full Text]
![]()
![]()
![]()

![]()
![]()
![]()
Y. Li, J. Kang, J. Friedman, L. Tarassishin, J. Ye, A. Kovalenko, D. Wallach, and M. S. Horwitz
Identification of a cell protein (FIP-3) as a modulator of NF-kappa B activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha -induced apoptosis
PNAS,
February 2, 1999;
96(3):
1042 - 1047.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
Y. F. Liu, D. Dorow, and J. Marshall
Activation of MLK2-mediated Signaling Cascades by Polyglutamine-expanded Huntingtin
J. Biol. Chem.,
June 16, 2000;
275(25):
19035 - 19040.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
M. F. Peters and C. A. Ross
Isolation of a 40-kDa Huntingtin-associated Protein
J. Biol. Chem.,
January 26, 2001;
276(5):
3188 - 3194.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
A. Khoshnan, J. Ko, and P. H. Patterson
Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity
PNAS,
January 22, 2002;
99(2):
1002 - 1007.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
S. Holbert, I. Denghien, T. Kiechle, A. Rosenblatt, C. Wellington, M. R. Hayden, R. L. Margolis, C. A. Ross, J. Dausset, R. J. Ferrante, et al.
The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis
PNAS,
February 13, 2001;
98(4):
1811 - 1816.
[Abstract]
[Full Text]
[PDF]
![]()
This Article ![]()
![]()
Abstract
![]()
FREE Full Text (PDF)
![]()
Alert me when this article is cited
![]()
Alert me if a correction is posted
![]()
Services ![]()
![]()
Email this article to a friend
![]()
Similar articles in this journal
![]()
Similar articles in ISI Web of Science
![]()
Similar articles in PubMed
![]()
Alert me to new issues of the journal
![]()
Add to My Personal Archive
![]()
Download to citation manager
![]()
Search for citing articles in:
ISI Web of Science (151)
![]()
Request Permissions ![]()
Google Scholar ![]()
![]()
Articles by Faber, P. W.
![]()
Articles by MacDonald, M. E.
![]()
Search for Related Content
![]()
PubMed ![]()
![]()
PubMed Citation
![]()
Articles by Faber, P. W.
![]()
Articles by MacDonald, M. E.
![]()
Social Bookmarking ![]()
![]()
What's this?